Abstract
Purpose of the study Today, use of antiretroviral (ARV) therapy in patients with AIDS is associated with longer survival [1]. However, several new complications have been described in the last few years, mainly cardiovascular events. Several abnormalities have been related to cardiovascular complications: endothelial dysfunction, dyslipidemia, insulin resistance, or prothrombotic state. However, none of these entities totally explain cardiovascular complications. The aim of this research was to determine the frequency of SPS associated with ARV therapy.
Highlights
We studied 100 patients with AIDS: four women and 96 men
We found that 73% of the patients had criteria to be considered carriers of SPS
The analysis of results according to the group of study showed that 54.8% of patients with SPS were receiving protease inhibitors (p = 0.239)
Summary
Address: Carlos MacGregor, IMSS, Mexico City, Mexico * Corresponding author from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 9–13 November 2008. Address: Carlos MacGregor, IMSS, Mexico City, Mexico * Corresponding author from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. Published: 10 November 2008 Journal of the International AIDS Society 2008, 11(Suppl 1):P104 doi:10.1186/1758-2652-11-S1-P104. Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf . Use of antiretroviral (ARV) therapy in patients with AIDS is associated with longer survival [1]. Several abnormalities have been related to cardiovascular complications: endothelial dysfunction, dyslipidemia, insulin resistance, or prothrombotic state. None of these entities totally explain cardiovascular complications. The aim of this research was to determine the frequency of SPS associated with ARV therapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
